These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16644710)

  • 1. Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E?
    Dallinga-Thie GM; van Tol A; Hattori H; Rensen PC; Sijbrands EJ
    Diabetes; 2006 May; 55(5):1491-6. PubMed ID: 16644710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein.
    Dallinga-Thie GM; van Tol A; Dullaart RP;
    Biochim Biophys Acta; 2009 Aug; 1791(8):714-8. PubMed ID: 19303940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.
    Dallinga-Thie GM; van Tol A; Hattori H; van Vark-van der Zee LC; Jansen H; Sijbrands EJ;
    Diabetologia; 2006 Jul; 49(7):1505-11. PubMed ID: 16752169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes.
    Bach-Ngohou K; Ouguerram K; Frénais R; Maugère P; Ripolles-Piquer B; Zaïr Y; Krempf M; Bard JM
    J Pharmacol Exp Ther; 2005 Oct; 315(1):363-9. PubMed ID: 16014756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes.
    van Hoek M; van Tol A; van Vark-van der Zee LC; Jansen H; Kastelein JJ; Sijbrands EJ; Dallinga-Thie GM
    Curr Med Res Opin; 2009 Jan; 25(1):93-101. PubMed ID: 19210142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma apolipoprotein E concentration is an important determinant of phospholipid transfer protein activity in type 2 diabetes mellitus.
    Tan KC; Shiu SW; Wong Y; Wong WK; Tam S
    Diabetes Metab Res Rev; 2006; 22(4):307-12. PubMed ID: 16389649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes.
    van Venrooij FV; Stolk RP; Banga JD; Sijmonsma TP; van Tol A; Erkelens DW; Dallinga-Thie GM;
    Diabetes Care; 2003 Apr; 26(4):1216-23. PubMed ID: 12663600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
    Dallinga-Thie GM; Berk-Planken II; Bootsma AH; Jansen H;
    Diabetes Care; 2004 Jun; 27(6):1358-64. PubMed ID: 15161788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group
    Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
    Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
    Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein.
    Settasatian N; Barter PJ; Rye KA
    J Lipid Res; 2008 Jan; 49(1):115-26. PubMed ID: 17921435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome.
    Ooi EM; Ng TW; Watts GF; Chan DC; Barrett PH
    J Lipid Res; 2012 Nov; 53(11):2443-9. PubMed ID: 22930812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
    Charlton-Menys V; Betteridge DJ; Colhoun H; Fuller J; France M; Hitman GA; Livingstone SJ; Neil HA; Newman CB; Szarek M; DeMicco DA; Durrington PN
    Diabetologia; 2009 Feb; 52(2):218-25. PubMed ID: 18972097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
    Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
    Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins of different brain penetrability differentially affect CSF PLTP activity.
    Vuletic S; Riekse RG; Marcovina SM; Peskind ER; Hazzard WR; Albers JJ
    Dement Geriatr Cogn Disord; 2006; 22(5-6):392-8. PubMed ID: 16960448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active plasma phospholipid transfer protein is associated with apoA-I- but not apoE-containing lipoproteins.
    Cheung MC; Albers JJ
    J Lipid Res; 2006 Jun; 47(6):1315-21. PubMed ID: 16520487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
    Betteridge DJ; Gibson JM
    Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria.
    Dogra GK; Watts GF; Chan DC; Stanton K
    Diabet Med; 2005 Mar; 22(3):239-42. PubMed ID: 15717868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.